Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave

Eli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite its premium pricing, even as lower-cost semaglutide generics prepare to enter the Indian market.Winselow Tucker, president and general manager of Eli Lilly and Company (India), told ET that the company sees room for both branded innovator drugs and generics to thrive simultaneously in the rapidly expanding domestic segment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ks8Hj03
via IFTTT

Read More

All our AI models have scientists in loop, says MSD chief AI officer

MSD's Chief AI Officer, Anton Groom, highlights AI's transformative role in drug discovery. AI models like TEDDY and KERMT are assisting scientists, identifying new drug targets and refining lead identification. This technology is accelerating the development of new medicines, with two AI-discovered molecules already in clinical trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/utByhpW
via IFTTT

Read More

Brain can keep producing new neurons in old age, but Alzheimer’s may disrupt the process: Study

New research reveals the adult brain generates fresh nerve cells in the hippocampus, vital for memory. This ability declines in Alzheimer's patients. Scientists observed this process in postmortem brain samples. Healthy older adults show continued neuron production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CarbWi1
via IFTTT

Read More

ACC clears Dr Rajeev Singh Raghuvanshi’s reappointment as Drugs Controller (India)

Dr Rajeev Singh Raghuvanshi will continue as Drugs Controller (India) at CDSCO. His reappointment is on a contract basis for one year starting March 1, 2026. This decision follows a proposal from the Department of Health and Family Welfare. Dr Raghuvanshi heads the CDSCO, responsible for drug quality and new drug approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8FeGzSH
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod to market generic drugs

Zydus Lifesciences has won regulatory clearance in the United States to launch generic Ivermectin and Dapsone tablets. Used to treat parasitic worm infections and leprosy, the approval signals progress in the company's US growth strategy and broadens its market footprint.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mQ4rfo7
via IFTTT

Read More

Abbott signs pact with Novo Nordisk to offer semaglutide

Semaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic drug makers has already lined up the launch of their generic semaglutide drugs immediately after the patent expiry, prompting the company to brace up for the upcoming competition in the GLP-1 market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SUgAmZw
via IFTTT

Read More

Lupin receives USFDA EIR for Goa facility with VAI status

Drug maker Lupin said it has received an Establishment Inspection Report from the US Food and Drug Administration for its Goa-based manufacturing facility, with a Voluntary Action Indicated classification following a November 2025 inspection.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rp3wNg6
via IFTTT

Read More